Loading stock data…
MDXH
$2.06+0.02 (+0.98%)
Market ClosedLast close May 1
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MDxHealth SA in the Healthcare sector is trading at $2.06. The stock is currently near its 52-week low of $1.67, remaining 39.4% below its 200-day moving average. Technical signals show neutral RSI of 46 and bullish MACD crossover, explaining why MDXH maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.06
Potential Upside
5%
Whystock Fair Value$2.16
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that meas...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$111.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-537543.56
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
277.15%
Volume
Today's trading volume
126,641
Recent News
MDxHealth S.A. Q4 2025 Earnings Call Summary
Moby summary of MDxHealth S.A.'s Q4 2025 earnings call
MDxHealth SA (MDXH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising Losses
MDxHealth SA (MDXH) reports a 19% revenue increase and significant unit growth, but faces challenges with increased losses and cash flow concerns.
MDxHealth (MDXH) Q4 2025 Earnings Call Transcript
Michael McGarrity: Thanks, John, and thank you all for joining us for our fourth quarter and full year 2025 earnings conference call for MDxHealth S.A. With me today is Ron Kalfus, who has returned as our Interim Chief Financial Officer. Over the past few years, operating discipline, commercial execution, and an aggressive growth strategy have positioned MDxHealth S.A. as the leader in precision diagnostics focused in urology.
MDxHealth Q4 Earnings Call Highlights
MDxHealth (NASDAQ:MDXH) reported fourth-quarter and full-year 2025 results and provided 2026 guidance, with management highlighting continued revenue growth, ongoing integration work following the ExoDx acquisition, and expectations for improving profitability over the course of 2026. Management fr
Loss-Making MDxHealth SA (NASDAQ:MDXH) Expected To Breakeven In The Medium-Term
With the business potentially at an important milestone, we thought we'd take a closer look at MDxHealth SA's...